Observed improvements in immune parameters and behavioral symptoms following low-dose IL-2 treatment in four autistic children with immune dysfunction.

Four autistic children (age 6) with immune problems received a medication called low-dose IL-2. All children showed significant improvements in autism symptoms, including better communication, behavior, and sleep. The improvements lasted at least 3 months with no side effects. Blood tests showed their immune systems became more balanced. While promising, this is only a small case study and needs much larger research to confirm if this treatment really works.

This case report describes four autistic children (average age 6 years) who received low-dose Interleukin-2 (Ld IL-2) treatment for immune dysfunction. All participants showed marked behavioral improvements across multiple assessment scales including CARS, ABC, ATEC, and CABS, with no adverse events reported. Improvements persisted for three months post-treatment, particularly in speech/language/communication and body/health/behavior domains. Caregivers reported improved sleep quality and overall physical health.

Immune testing revealed decreased Type 1 cytotoxic T cells and improved Tc1/Regulatory T cell ratios. The findings suggest a potential association between Ld IL-2 treatment and ASD symptom improvement through immune modulation, though this represents preliminary case report evidence requiring larger controlled studies.

While these preliminary findings suggest potential benefits of Ld IL-2 for autistic children with immune dysfunction, the evidence is too limited for clinical recommendations. Larger randomized controlled trials are essential before considering this intervention. Parents should discuss any experimental treatments with qualified medical professionals.

This is a case report of only four children with no control group or randomization. The study lacks blinding, has potential selection bias from a larger cohort, and provides insufficient data for comprehensive safety assessment. Findings cannot establish causation or generalizability.

Autism spectrum disorder (ASD) is a complex neurodevelopmental condition for which there are no definitive medications targeting core symptoms. Growing evidence indicates that individuals with ASD exhibit immune dysfunction and evidence of peripheral and central inflammation. Immunotherapy interventions have shown promise in addressing this dysregulation. Notably, low-dose Interleukin-2 (Ld IL-2), an established treatment for certain autoimmune diseases, represents a potential therapeutic approach.

Our study aims to investigate the association between Ld IL-2-induced immune modulation and behavioral improvements in children with ASD. This research may offer novel insights into potential treatment strategies for ASD. In our previously completed single-arm, self-controlled clinical study (data unpublished), 24 ASD children with immune abnormalities received Ld IL-2 treatment, all of whom showed varying degrees of symptom improvement. This paper presents case reports of four ASD children who demonstrated marked clinical improvement and substantial correction of immune imbalance following treatment.

The average age of 4 participants was approximately 6 years old, comprising two boys and two girls. Assessments using the Childhood Autism Rating Scale(CARS), Aberrant Behavior Checklist (ABC), Autism Treatment Evaluation Checklist (ATEC), Krug's Autism Behavior Scale (CABS), Hospital Anxiety and Depression Scale (HADS), and Caregiver Strain Questionnaire (CGSQ)revealed substantial behavioral improvements and no adverse events. Improvements persisted for three months post-treatment, with notable progress in Speech/Language/Communication and body/health/behavior domains. According to caregivers, there has been a observed improvement in the subjects' sleep quality, accompanied by a gradual restoration of overall physical health.

Immune testing in the four pediatric patients revealed a marked decrease in both the proportion of Type 1 cytotoxic T cells (Tc1) and the Tc1/Regulatory T cell ratio. Our findings in these four cases describe an association between Ld IL-2 treatment and observed improvements in ASD symptoms, potentially linked to immune modulation.